These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
222 related articles for article (PubMed ID: 21063228)
1. The economic burden of late entry into medical care for patients with HIV infection. Fleishman JA; Yehia BR; Moore RD; Gebo KA; Med Care; 2010 Dec; 48(12):1071-9. PubMed ID: 21063228 [TBL] [Abstract][Full Text] [Related]
2. The high cost of medical care for patients who present late (CD4 <200 cells/microL) with HIV infection. Krentz HB; Auld MC; Gill MJ HIV Med; 2004 Mar; 5(2):93-8. PubMed ID: 15012648 [TBL] [Abstract][Full Text] [Related]
3. Medical resource utilization and cost of HIV-related care in the highly active antiretroviral therapy era at a University Clinic in Sweden. Ghatnekar O; Hjortsberg C; Gisslén M; Lindbäck S; Löthgren M Pharmacoeconomics; 2010; 28 Suppl 1():49-57. PubMed ID: 21182343 [TBL] [Abstract][Full Text] [Related]
4. Hospital and outpatient health services utilization among HIV-infected adults in care 2000-2002. Fleishman JA; Gebo KA; Reilly ED; Conviser R; Christopher Mathews W; Todd Korthuis P; Hellinger J; Rutstein R; Keiser P; Rubin H; Moore RD; Med Care; 2005 Sep; 43(9 Suppl):III40-52. PubMed ID: 16116308 [TBL] [Abstract][Full Text] [Related]
5. Contemporary costs of HIV healthcare in the HAART era. Gebo KA; Fleishman JA; Conviser R; Hellinger J; Hellinger FJ; Josephs JS; Keiser P; Gaist P; Moore RD; AIDS; 2010 Nov; 24(17):2705-15. PubMed ID: 20859193 [TBL] [Abstract][Full Text] [Related]
6. Costs to Medicaid of advancing immunosuppression in an urban HIV-infected patient population in Maryland. Moore RD; Chaisson RE J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Mar; 14(3):223-31. PubMed ID: 9117454 [TBL] [Abstract][Full Text] [Related]
7. Decreased medical expenditures for care of HIV-seropositive patients. The impact of highly active antiretroviral therapy at a US Veterans Affairs Medical Center. Mole L; Ockrim K; Holodniy M Pharmacoeconomics; 1999 Sep; 16(3):307-15. PubMed ID: 10558042 [TBL] [Abstract][Full Text] [Related]
8. The changing direct costs of medical care for patients with HIV/AIDS, 1995-2001. Krentz HB; Auld MC; Gill MJ; CMAJ; 2003 Jul; 169(2):106-10. PubMed ID: 12874156 [TBL] [Abstract][Full Text] [Related]
9. Costs of HIV medical care in the era of highly active antiretroviral therapy. Gebo KA; Chaisson RE; Folkemer JG; Bartlett JG; Moore RD AIDS; 1999 May; 13(8):963-9. PubMed ID: 10371178 [TBL] [Abstract][Full Text] [Related]
10. Variations in the care of HIV-infected adults in the United States: results from the HIV Cost and Services Utilization Study. Shapiro MF; Morton SC; McCaffrey DF; Senterfitt JW; Fleishman JA; Perlman JF; Athey LA; Keesey JW; Goldman DP; Berry SH; Bozzette SA JAMA; 1999 Jun 23-30; 281(24):2305-15. PubMed ID: 10386555 [TBL] [Abstract][Full Text] [Related]
11. Updated direct costs of medical care for HIV-infected patients within a regional population from 2006 to 2017. Krentz HB; Vu Q; Gill MJ HIV Med; 2020 May; 21(5):289-298. PubMed ID: 31852032 [TBL] [Abstract][Full Text] [Related]
12. Hospital and outpatient health services utilization among HIV-infected patients in care in 1999. HIV Research Network J Acquir Immune Defic Syndr; 2002 May; 30(1):21-6. PubMed ID: 12048359 [TBL] [Abstract][Full Text] [Related]
13. Cost of treating seriously mentally ill persons with HIV following highly active retroviral therapy (HAART). Rothbard AB; Lee S; Blank MB J Ment Health Policy Econ; 2009 Dec; 12(4):187-94. PubMed ID: 20195006 [TBL] [Abstract][Full Text] [Related]
14. Predicting HIV care costs using CD4 counts from clinical trials. Hill A; Gebo K Am J Manag Care; 2007 Sep; 13(9):524-8. PubMed ID: 17803366 [TBL] [Abstract][Full Text] [Related]
15. Cost of treatment in a US commercially insured, HIV-1-infected population. Solem CT; Snedecor SJ; Khachatryan A; Nedrow K; Tawadrous M; Chambers R; Haider S; Simpson K PLoS One; 2014; 9(5):e98152. PubMed ID: 24866200 [TBL] [Abstract][Full Text] [Related]
16. Effect of management strategies and clinical status on costs of care for advanced HIV. Barnett PG; Chow A; Joyce VR; Bayoumi AM; Griffin SC; Sun H; Holodniy M; Brown ST; Cameron W; Sculpher M; Youle M; Anis AH; Owens DK Am J Manag Care; 2014 May; 20(5):e129-37. PubMed ID: 25326927 [TBL] [Abstract][Full Text] [Related]
17. Updates of lifetime costs of care and quality-of-life estimates for HIV-infected persons in the United States: late versus early diagnosis and entry into care. Farnham PG; Gopalappa C; Sansom SL; Hutchinson AB; Brooks JT; Weidle PJ; Marconi VC; Rimland D J Acquir Immune Defic Syndr; 2013 Oct; 64(2):183-9. PubMed ID: 23615000 [TBL] [Abstract][Full Text] [Related]
18. Modifications of health resource-use in Italy after the introduction of highly active antiretroviral therapy (HAART) for human immunodeficiency virus (HIV) infection. Pharmaco-economic implications in a population-based setting. Torti C; Casari S; Palvarini L; Quiros-Roldan E; Moretti F; Leone L; Patroni A; Castelli F; Ripamonti D; Tramarin A; Carosi G Health Policy; 2003 Sep; 65(3):261-7. PubMed ID: 12941493 [TBL] [Abstract][Full Text] [Related]
19. The financial burden of morbidity in HIV-infected adults on antiretroviral therapy in Côte d'Ivoire. Beaulière A; Touré S; Alexandre PK; Koné K; Pouhé A; Kouadio B; Journy N; Son J; Ettiègne-Traoré V; Dabis F; Eholié S; Anglaret X PLoS One; 2010 Jun; 5(6):e11213. PubMed ID: 20585454 [TBL] [Abstract][Full Text] [Related]
20. Expenditures for the care of HIV-infected patients in rural areas in China's antiretroviral therapy programs. Zhou F; Kominski GF; Qian HZ; Wang J; Duan S; Guo Z; Zhao X BMC Med; 2011 Jan; 9():6. PubMed ID: 21241494 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]